STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
radiology-2

Intuitive Surgical Q3 2024 Earnings: Robust Growth Amid Market Challenges

byLuca Blaumann
October 18, 2024
in Biotechnology, Medical Devices, Mid-Cap
Reading Time: 3 mins read
Share on TwitterShare on LinkedIn

Key Factors to Watch as da Vinci V Expansion Continues

Intuitive Surgical (ISRG) has reported strong third-quarter financial results for 2024, with revenues totaling $2.04 billion, in line with consensus estimates. The company posted earnings per share (EPS) of $1.56, exceeding market expectations of $1.37. These results were buoyed by strong sales growth in both the U.S. and international markets, along with the ongoing ramp-up of its da Vinci V surgical system (dV5). However, despite this solid performance, challenges lie ahead, particularly as the company navigates a saturated U.S. market, competitive pressures, and questions surrounding the value proposition of the dV5 system.

Strong Revenue Growth but Competitive Challenges Loom

Intuitive Surgical saw robust revenue growth, with U.S. revenues up 17% year-over-year to $1.38 billion. This included a notable 23% increase in system revenues, which reached $265 million. The company’s international (OUS) revenues grew by 17% to $659 million, with system revenues contributing $180 million, reflecting a 10% year-over-year rise. Instrument and accessory (I&A) revenue, a critical component of Intuitive’s business model, grew by 18%, although it slightly missed analyst expectations.

The solid revenue figures were driven in part by the increased placement of da Vinci systems globally. Intuitive placed 110 da Vinci V systems in the U.S. during the quarter, representing a significant jump from the 70 placements in Q2. The company continues to expand internationally, with new regulatory clearances in South Korea and discussions underway in Japan. While these placements reflect the company’s strong market position, questions remain about the long-term value of the dV5 system, which comes at a 30% premium compared to the previous Xi model.

da Vinci V: The Critical Growth Driver

The da Vinci V system has been a focal point of Intuitive Surgical’s growth strategy, but its economic value remains unclear. While initial uptake has been promising, with 180 dV5 systems placed in the first two quarters of its availability (compared to 104 Xi systems), the long-term success of this new model will depend on its ability to demonstrate clear advantages over its predecessor. Analysts remain cautious about whether hospitals will be willing to pay the 30% price premium for the dV5, especially in the face of rising competition from Medtronic and other surgical robotics companies.

In terms of procedures, Intuitive reported an 18% year-over-year increase in total procedures, with U.S. growth at 16% and international growth at 24%. However, the company’s overall installed base has seen a slight increase in unused capacity, particularly outside the U.S., where 42% of system capacity remains idle. This could pose challenges to future revenue growth if demand does not catch up with system installations.

Valuation and Investment Outlook

Despite the company’s strong financial performance, its valuation remains a point of concern. Intuitive is trading at approximately 18 times forward price-to-sales and 74 times forward price-to-earnings, which suggests that the stock is priced for perfection. The market appears to have already baked in expectations for continued growth, leaving little room for error. Any missteps, such as slower-than-expected dV5 adoption or increased competition, could weigh on the stock’s performance.

The company also faces headwinds from potential new entrants in the market. Medtronic is expected to launch its own robotic surgery system in the U.S. by mid-2025, which could put pressure on Intuitive’s market share. Additionally, Chinese competitors are eyeing international markets, adding further uncertainty to Intuitive’s long-term outlook.

Final Thoughts

Intuitive Surgical’s Q3 2024 results reflect a company that continues to deliver solid growth, both in the U.S. and internationally. The ongoing ramp-up of the da Vinci V system, combined with steady procedure growth, positions the company well for the future. However, the high valuation, combined with competitive pressures and questions surrounding the value of the dV5 system, warrants caution. Investors will be closely watching the company’s next earnings report and any developments in its competitive landscape, particularly as Medtronic’s launch looms on the horizon.

For now, Intuitive Surgical remains a leader in the robotic surgery space, but it will need to navigate several challenges to maintain its dominant position.

You might like this article:Ulta Beauty: Long-Term Prospects Shine Amidst Industry Challenges

Tags: analystBreakingGrowthMoversNewsStock Market
Previous Post

Ulta Beauty: Long-Term Prospects Shine Amidst Industry Challenges

Next Post

Netflix Surges After Strong Q3 Results and Ad-Supported Tier Momentum

Related Posts

KULR Expands Bitcoin Treasury to $78 Million, Strengthens Crypto-Centric Financial Strategy

byLuca Blaumann
May 20, 2025
0

With 800 BTC and 220% Yield, KULR Reinforces Commitment to Bitcoin as a Strategic Asset KULR Technology Group (KULR), a...

KindlyMD and Nakamoto Merge to Launch Largest Bitcoin Treasury Initiative in Public Markets

byLuca Blaumann
May 12, 2025
0

$710 Million Raised as David Bailey Leads Ambitious Plan to Transform Bitcoin Adoption Through Public Equity In a landmark move...

drugs-3

Hims & Hers Health Doubles Revenue in Q1 2025, Raises Full-Year Outlook

byLuca Blaumann
May 5, 2025
0

Surging subscriber growth and profitability prompt ambitious long-term targets for 2030 Hims & Hers Health, Inc. (HIMS), a leading digital...

Next Post

Netflix Surges After Strong Q3 Results and Ad-Supported Tier Momentum

Latest News

Marvell Projects Strong Q2 Growth on AI Chip Demand Surge

Nvidia Surges as AI Momentum Outweighs China Setbacks in Q1 Earnings

Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss

Macy’s Beats Q1 Estimates But Cuts 2025 Outlook Amid Retail Headwinds

Bitcoin Smashes Through $111K Amid Regulatory Optimism and Institutional Demand

Based on Your Interest

Pharmaceuticals

Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program

May 21, 2025
tesla-2
Mega-Cap

Elon Musk Confirms Tesla and xAI to Continue Buying AI Chips from Nvidia and AMD

May 21, 2025
Aerospace & Defense

KULR Expands Bitcoin Treasury to $78 Million, Strengthens Crypto-Centric Financial Strategy

May 20, 2025

Recommended

Internet

Reddit Stock: Undervalued Gem in the Social Media Landscape

May 20, 2025
Large-Cap

AMD to Sell ZT Systems Manufacturing Business to Sanmina in $3 Billion Deal

May 19, 2025
Large-Cap

Dick’s Sporting Goods to Acquire Foot Locker in $2.4 Billion Deal

May 16, 2025
Large-Cap

AMD Expands Stock Buyback Program to $10 Billion Amid Strong Financial Confidence

May 14, 2025
Brokerages

Coinbase Surges After Landmark S&P 500 Inclusion

May 13, 2025
Stoxpo

Follow us on social media:

Highlights

  • Marvell Projects Strong Q2 Growth on AI Chip Demand Surge
  • Nvidia Surges as AI Momentum Outweighs China Setbacks in Q1 Earnings
  • Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss
  • Macy’s Beats Q1 Estimates But Cuts 2025 Outlook Amid Retail Headwinds
  • Bitcoin Smashes Through $111K Amid Regulatory Optimism and Institutional Demand

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

investing

Marvell Projects Strong Q2 Growth on AI Chip Demand Surge

May 29, 2025
semiconductor-2

Nvidia Surges as AI Momentum Outweighs China Setbacks in Q1 Earnings

May 29, 2025
opthalmology

Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss

May 29, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?